Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase IB/II Trial.
Phase of Trial: Phase I/II
Latest Information Update: 23 Dec 2014
At a glance
- Drugs Cetuximab (Primary) ; Sorafenib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 02 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 16 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.